We thank Drs Kelley and Incze [1] for taking time to offer feedback on our report of defining a core outcomes set for opioid use disorder trials (OUD-COS) [2]. The major points they make are outlined in the paper's limitations, and we concur that the process would have benefited from broader stakeholder input, including most critically that of people who use drugs.We hope that the results of our time-limited work form a version 1 of the OUD-COS. As others consider the next steps toward strengthening this core outcomes set, the availability of resources will be essential to successfully broaden the work and the contribution of diverse stakeholders. Although the COVID-19 pandemic significantly impacted the timing and ability of our group to function, we remain confident that our project has taken an initial step toward the goal of supporting consistency in measurement in this essential public health area. We have taken a first step, but there are clearly additional steps to go. We are very much willing to support and collaborate on any future endeavors.